|
FY2022
12 months to Jun 30, 2022
|
FY2021
0 months to Jul 14, 2021
|
FY2016
12 months to Dec 31, 2015
|
FY2014
12 months to Dec 31, 2013
|
FY2013
12 months to Dec 31, 2012
|
|
|---|---|---|---|---|---|
| Net loss | |||||
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||
| Depreciation | |||||
| Amortization of intangibles | |||||
| Impairment of intangibles | |||||
| Amortization of right-of-use assets | |||||
| Amortization of deferred financing costs | |||||
| Impairment and other losses (gains), net | |||||
| Stock-based compensation | |||||
| Common stock issuances | |||||
| Warrants related to financing of convertible note payable | |||||
| Imputed interest for note payable | |||||
| Loss contingency on equity issuance | |||||
| Gain on change in fair value of derivative liabilities | |||||
| Discount on derivative liability | |||||
| Provision (reversal) for bad debt | |||||
| Preferred shares converted to common stock | |||||
| Beneficial conversion features on convertible promissory notes | |||||
| Tax provision on income | |||||
| Change in operating assets and liabilities: | |||||
| Accounts receivable | |||||
| Prepaid expenses | |||||
| Accounts payable and accrued expenses | |||||
| Other assets | |||||
| Operating lease liability | |||||
| Due to related parties | |||||
| Other long-term liabilities | |||||
| Contract liabilities relating to revenue | |||||
| Contract liabilities to government grant | |||||
| Net cash used used in operating activities | |||||
| CASH FLOWS FROM INVESTING ACTIVITIES: | |||||
| Net cash paid for acquisition of Converge | |||||
| Net cash paid for acquisition of Redeeem | |||||
| Purchase of fixed assets | |||||
| Net cash used in investing activities | |||||
| CASH FLOWS FROM FINANCING ACTIVITIES: | |||||
| Proceeds from notes payable - related party | |||||
| Proceeds from bank loan, net of debt issuance cost | |||||
| Proceeds from the issuance of preferred stock, net of offering costs | |||||
| Proceeds from initial public offering, net of offering costs | |||||
| Proceeds from stimulus loan programs | |||||
| Principal payments made for bank loan | |||||
| Payments to note payable of related party | |||||
| Payments made for the redemption of Series E preferred stock | |||||
| Proceeds from convertible note payable | |||||
| Payments to convertible note payable | |||||
| Net cash provided by financing activities | |||||
| Effect of exchange rate on cash | |||||
| Net increase in cash, cash equivalents | |||||
| CASH AND CASH EQUIVALENTS — beginning of year | |||||
| CASH AND CASH EQUIVALENTS - end of years | |||||
| CASH AND CASH EQUIVALENTS — end of year | |||||
| Cash paid during the period for: | |||||
| Income taxes | |||||
| Interest expense | |||||
| Noncash investing and financing activities: | |||||
| Preferred shares converted into common stock upon uplisting | |||||
| Shares to be issued for Converge acquisition | |||||
| Shares to be issued for Redeeem acquisition | |||||
| Issuance of common stock related to convertible note payable | |||||
| Issuance of common stock related to stock payable | |||||
| Right-of-use assets acquired through operating leases | |||||
Loading...